The effect will usually be better after repeated administration of veentuzumab/Bisi a few times

The recommended dosage regimen for the treatment of bladder cancer with venetuzumab/Enfortumab is 1.25 mg/kg, which should be infused intravenously every two weeks. The duration of treatment depends on the patient's clinical response and tolerance. At least two to three infusions are usually recommended early in treatment to assess patient tolerance and initial efficacy of the drug. Most clinical experience shows that after two to three cycles of treatment, tumor volume, imaging indicators and biomarkers begin to show an improvement trend. This stage is considered a critical observation period for the initial efficacy.

In practical applications, the efficacy of veentuzumab not only depends on the number of infusions, but is also closely related to the severity of the patient's condition, Nectin-4 expression level, previous treatment regimens and the use of combined drugs. Some patients can achieve significant tumor remission and symptom improvement after four to six consecutive infusions. For patients who respond quickly to the course of treatment, early imaging evaluation can show the efficacy and provide a reference for subsequent adjustment of the course of treatment. For patients with larger body weight or extensive disease, veentuzumab may need to be adjusted according to the actual dose and the treatment course extended to ensure the maximum anti-tumor effect.

Clinical practice emphasizes the importance of individualized monitoring. Adverse reactions, such as skin reactions, peripheral nerve symptoms and changes in hematological indicators, need to be observed after each infusion, and the treatment course adjustment should be judged based on imaging follow-up. Generally speaking, continuous and stable multiple infusions are the prerequisite to ensure efficacy and maintain remission. Premature discontinuation may lead to disease rebound or insufficient remission. For the vast majority of patients with advanced urothelial cancer, standard treatment is usually recommended until disease progression or intolerable side effects occur.

In general, with an infusion frequency of once every two weeks, the initial efficacy of veentuzumab can be observed after two to three courses of treatment in the early stage of treatment, and multiple consecutive courses of treatment can help consolidate the tumor remission effect.

Reference: https://www.padcev.com/